OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 371 - 380 of 696 studies

Optimisation of breast cancer detection using X-rays

Anonymised copies of normal and abnormal digital mammograms are collected from clinical sites. Real and simulated images of lesions are used to measure the ability of radiologists to detect breast cancer when various technical factors are adjusted.

GO TO STUDY Go

Neurological

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB101/ION464 Administered Intrathecally to Adults with Multiple System Atrophy (MSA). (HORIZON)

This is a first-in-human, randomised (treatment is assigned by chance), study to evaluate the safety, tolerability and the pharmacokinetics [how a drug is processed] (PK) of multiple doses of the study drug (BIIB101) in adults with Multiple System Atrophy (MSA). Participants will receive either the study drug or a placebo (medication made of an inactive material). The study drug has been tested in animals but, since the study drug has not yet been tested in humans, the safety in ...

GO TO STUDY Go

Reproductive health and childbirth

Evaluation of Laboratory Methods for Measuring the Composition of Breast Milk

Aim: To establish laboratory tests for measuring the composition of human breast milk Outline of research: This study involves the collection of 1-2 teaspoons of breast milk (up to 10 mls) from up to 30 women who are already expressing milk for their babies in the Oxford Newborn Care Unit, Women’s Centre, John Radcliffe Hospital, Oxford The women are healthy volunteers and are recruited by virtue that their babies are NHS patients. Duration of participant involvement will be around 45 min. ...

GO TO STUDY Go

Cancer and neoplasms

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.

CCS1477 is a new experimental medication (sponsored by CellCentric Ltd) for a group of cancers that effect the blood and/or bone marrow. These include Acute Myeloid Leukaemia (AML), high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma (NHL). It is aimed at tumours that are not responsive to, or have become resistant to, existing medications used in late stage disease. The purpose of this study is to examine the safety, tolerability, pharmacokinetics (PK) and efficacy of CCS1477 when treating patients ...

GO TO STUDY Go

Cancer and neoplasms

Evaluation of the role of tongue base MucOsectomy and Step sErial Sectioning in the management of the unknown primary squamous cell cancer in the head and neck (MOSES).

Squamous cell carcinoma (SCC) is a cancer that originates from the cells lining the body and can spread into the lymph glands and beyond. Some patients first present with an SCC which has moved to the lymph glands of the neck. Clinical examination and imaging investigations are performed to try and identify the site where the cancer has originated. However, if no original site can be identified, then we call these ‘cancers of an unknown primary’ (CUP) of the head and ...

GO TO STUDY Go

Neurological

The PURA Global Network. Understanding PURA syndrome. PURA Syndrome Longitudinal Natural History Study (a Musketeers Memorandum study

PURA Syndrome was first described in 2014 in a small cohort of children, and since then just over 250 individuals have been identified to have the condition internationally. PURA syndrome typically causes severe developmental delay and intellectual disability. Many also suffer with hypotonia (severe floppiness), feeding difficulties and breathing abnormalities in infancy, and many develop seizures in early childhood. We are designing a longitudinal natural history study, with the aim to collect medical data on individuals with PURA Syndrome. We ...

GO TO STUDY Go

Cancer and neoplasms Oral and Gastrointestinal

Deep Liver Phenotyping & Immunology Study

Hepatocellular carcinoma (HCC) and cholangiocarcinoma are the two most common causes of primary liver cancer and HCC is the second highest cause of cancer death worldwide. It is known that most of these cancers occur in patients who already have a liver condition. Despite close monitoring of many patients who have liver disease with regular ultrasound scans, HCC and cholangiocarcinoma are often discovered at a late stage. This is because they rarely cause symptoms until they have ...

GO TO STUDY Go

Cancer and neoplasms

FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS). It is a multi-arm, multi-stage format, involving several different trial questions. FaR-RMS is intended to be a rolling programme of research with new treatment arms being introduced dependant on emerging data and innovation. This study has multiple aims. It aims to evaluate the impact of new agent regimens in both newly diagnosed and relapsed RMS; whether changing the duration of maintenance therapy affects outcome; and whether changes to dose, extent ...

GO TO STUDY Go

Oral and Gastrointestinal

Phase IIb, randomised, double-blind, placebo-controlled, multi-centre trial of infliximab with transcriptomic biomarker and mechanism evaluation in patients with acute pancreatitis

Acute pancreatitis is a serious condition in which the pancreas becomes inflamed and is damaged. It causes intense abdominal pain and may lead to multiple organ failure. Those suffering from the disease may need help with breathing, heart and kidney function. One out of twenty patients with acute pancreatitis dies, which is more likely to happen to those who develop organ failure. Treatment can be prolonged, often with extended stays in hospital of many weeks. To date many drugs have ...

GO TO STUDY Go

Renal and Urogenital

A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)

Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) are rare diseases that cause nephrosis. Patients suffer with debilitating oedema, and are at increased risk of infection and venous thromboembolism. Standard of care consists of high dose glucocorticoids, with associated morbidity including weight gain, diabetes, infection and osteoporosis. Patients require frequent hospital visits, hence these diseases carry a high socioeconomic burden. This is particularly high in FSGS, where patients with uncontrolled disease progress to end stage kidney disease (ESKD), at ...

GO TO STUDY Go